Phase II study of capecitabine, irinotecan, and celecoxib in advanced colorectal cancer.

被引：0
|
作者：
El-Rayes, BF
Shields, AF
Vaishampayan, U
Heilbrun, L
Bekaii-Saab, T
Zalupski, MM
Philip, PA
机构：
[1] Karmanos Canc Inst, Detroit, MI USA
[2] Ohio State Univ, Columbus, OH 43210 USA
[3] Univ Michigan, Ann Arbor, MI 48109 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3766
引用
收藏
页码：310S / 310S
页数：1
相关论文
共 50 条
  • [1] Phase II study of celecoxib, irinotecan, and capecitabine in patients with advanced colorectal cancer
    El-Rayes B
    Shields, A.
    Zalupski, M.
    Bekaii-Saab, T.
    Heilbrun, L.
    Vaishampayan, U.
    Manza, S.
    ANNALS OF ONCOLOGY, 2006, 17 : 70 - 70
  • [2] A phase II trial of celecoxib, irinotecan, and capecitabine in metastatic colorectal cancer.
    El-Rayes, BF
    Zalupski, MM
    Shields, AF
    Heilbrun, LK
    Bekaii-Saab, T
    Vaishampayan, U
    Philip, PA
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 290S - 290S
  • [3] Phase-II study of dose attenuated schedule of irinotecan, capecitabine, and celecoxib in advanced colorectal cancer
    Bassel F. El-Rayes
    Mark M. Zalupski
    Stephanie G. Manza
    Barbara Rusin
    Ann Marie Ferris
    Ulka Vaishampayan
    Lance K. Heilbrun
    Raghu Venkatramanamoorthy
    Anthony F. Shields
    Philip A. Philip
    Cancer Chemotherapy and Pharmacology, 2008, 61 : 283 - 289
  • [4] Phase-II study of dose attenuated schedule of irinotecan, capecitabine, and celecoxib in advanced colorectal cancer
    El-Rayes, Bassel F.
    Zalupski, Mark M.
    Manza, Stephanie G.
    Rusin, Barbara
    Ferris, Ann Marie
    Vaishampayan, Ulka
    Heilbrun, Lance K.
    Venkatramanamoorthy, Raghu
    Shields, Anthony F.
    Philip, Philip A.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2008, 61 (02) : 283 - 289
  • [5] A dose attenuated schedule of irinotecan and capecitabine in combination with celecoxib in advanced colorectal cancer.
    El-Rayes, B. F.
    Shields, A. F.
    Vaishampayan, U.
    Heilbrun, L. K.
    Zalupski, M. M.
    Philip, P. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 166S - 166S
  • [6] Phase II trial of irinotecan and capecitabine in patients with advanced colorectal cancer (ACRC)
    Ahn, JB
    Jung, KH
    Park, YS
    Kim, YH
    Chang, HJ
    Sohn, DK
    Lim, SB
    Choi, HS
    Jeong, SY
    Park, JG
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 299S - 299S
  • [7] Phase II study of weekly scheduled irinotecan and capecitabine treatment in advanced colorectal cancer patients.
    Li, Wenhua
    Li, Jin
    Xu, Jianming
    Shen, Lin
    Liu, Tianshu
    Guo, Wei Jian
    Zhang, Wen
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [8] A phase II study of capecitabine, oxaliplatin and irinotecan (XELOXIRI) as salvage therapy in patients with refractory metastatic colorectal cancer.
    Kwok, Gin Wai
    Leung, Roland Ching-Yu
    Chiu, Joanne
    Tang, Vikki
    Yau, Thomas Cheung
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [9] Phase II study of irinotecan (CPT 11) in patients whit not pretreated advanced colorectal cancer.
    Salgado, M
    Menéndez, D
    Sabin, P
    Diz, P
    Constenia-Figueiras, M
    Casai, J
    Calvo, L
    Castellanos, J
    Balcells, M
    Firvida, JL
    Irigoyen, A
    Quintero, G
    Garcia-Palomo, A
    García-Arroyo, FR
    Huidobro, G
    Valladares, M
    Garcia-Mata, J
    Vázquez, S
    De las Peñas, R
    Lorenzo, I
    Xaries, J
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S74 - S74
  • [10] Capecitabine in combination with oxaliplatin or irinotecan in elderly patients with advanced colorectal cancer: results of a randomized phase II study
    Rosati, G.
    Cordio, S.
    Bordonaro, R.
    Caputo, G.
    Novello, G.
    Reggiardo, G.
    Manzione, L.
    ANNALS OF ONCOLOGY, 2010, 21 (04) : 781 - 786
12345